Credit Suisse’s Apyx Medical APYX Stock Holding History

Credit Suisse’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17	Closed	–	–	4031
2022 Q2	$0	Buy	+17	New	+$87	﹤0.01%	3908

Other funds holding APYX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.25% 1-Year Est. Return

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Invenire Partners Ridgefield, Connecticut $65.4M AUM 18.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

Credit Suisse's APYX Position: Q3 2022 in Review

Credit Suisse sold out of Apyx Medical (APYX) in Q3 2022, closing a stake of 17 shares.

Credit Suisse first reported a position in APYX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 54 funds tracked by Wall St. Rank hold APYX as of Q3 2022.

Credit Suisse reported no remaining Apyx Medical position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 17 Apyx Medical shares in Q3 2022.
Credit Suisse first reported a position in Apyx Medical in Q2 2022 and held it in 1 quarter.
Credit Suisse's Apyx Medical position peaked at $0 in Q2 2022.
54 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.